Loading...
XPARSIGHT
Market cap33mUSD
Dec 23, Last price  
0.28EUR
1D
-0.54%
1Q
-25.41%
Jan 2017
-96.44%
IPO
-96.71%
Name

Gensight Biologics SA

Chart & Performance

D1W1MN
XPAR:SIGHT chart
P/E
—
P/S
25.51
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.58%
Rev. gr., 5y
-21.85%
Revenues
1m
-50.93%
908,4421,102,6933,559,9983,001,0003,702,0004,346,000700,0004,394,0005,276,0002,582,0001,267,000
Net income
-26m
L-5.08%
-2,762,861-6,671,142-13,653,620-22,081,663-24,112,000-33,453,000-30,710,000-34,016,000-28,617,000-27,624,000-26,220,000
CFO
-25m
L-26.93%
-1,950,097-5,516,392-12,094,554-19,641,790-18,782,000-28,383,000-28,112,000-15,044,000-17,139,000-33,753,000-24,663,000
Earnings
Mar 20, 2025

Profile

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
URL
https://www.gensight-biologics.com/
IPO date
Jul 13, 2016
Employees
45
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,267
-50.93%
2,582
-51.06%
5,276
20.07%
Cost of revenue
24,894
27,175
28,448
Unusual Expense (Income)
NOPBT
(23,627)
(24,593)
(23,172)
NOPBT Margin
Operating Taxes
(1,000)
5
2
Tax Rate
NOPAT
(23,626)
(24,598)
(23,174)
Net income
(26,220)
-5.08%
(27,624)
-3.47%
(28,617)
-15.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,918
(156)
28,228
BB yield
-17.63%
0.10%
-11.24%
Debt
Debt current
17,380
2,429
5,410
Long-term debt
2,871
12,084
9,403
Deferred revenue
193
420
Other long-term liabilities
13,496
16,167
10,799
Net debt
18,117
3,270
(29,475)
Cash flow
Cash from operating activities
(24,663)
(33,753)
(17,139)
CAPEX
(10)
(252)
(32)
Cash from investing activities
209
172
(16)
Cash from financing activities
15,859
95
23,739
FCF
(21,903)
(24,441)
(22,569)
Balance
Cash
2,134
10,610
44,288
Long term investments
633
Excess cash
2,071
11,114
44,024
Stockholders' equity
(221,639)
(26,467)
(27,459)
Invested Capital
222,861
40,170
67,210
ROIC
ROCE
EV
Common stock shares outstanding
48,316
46,330
45,151
Price
0.46
-86.32%
3.36
-39.53%
5.56
-22.02%
Market cap
22,226
-85.73%
155,762
-37.95%
251,037
0.23%
EV
40,343
356,680
387,906
EBITDA
(20,593)
(23,532)
(22,244)
EV/EBITDA
Interest
3,153
2,650
2,166
Interest/NOPBT